Analysts Offer Predictions for KYTX Q1 Earnings

Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) - Investment analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Kyverna Therapeutics in a research note issued on Monday, May 19th. HC Wainwright analyst M. Kapoor anticipates that the company will post earnings of ($0.87) per share for the quarter. HC Wainwright currently has a "Neutral" rating and a $4.00 target price on the stock. The consensus estimate for Kyverna Therapeutics' current full-year earnings is ($3.29) per share. HC Wainwright also issued estimates for Kyverna Therapeutics' Q2 2026 earnings at ($0.91) EPS, Q3 2026 earnings at ($0.96) EPS, Q4 2026 earnings at ($0.88) EPS and FY2026 earnings at ($3.62) EPS.

Separately, Morgan Stanley cut their target price on shares of Kyverna Therapeutics from $40.00 to $20.00 and set an "overweight" rating on the stock in a report on Tuesday, April 1st. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $18.33.

Kyverna Therapeutics Price Performance

Shares of Kyverna Therapeutics stock traded down $0.20 during trading on Tuesday, hitting $2.27. 524,822 shares of the company were exchanged, compared to its average volume of 421,119. The firm has a market capitalization of $98.11 million, a P/E ratio of -0.67 and a beta of 2.17. The firm's fifty day moving average price is $2.12 and its 200 day moving average price is $3.17. Kyverna Therapeutics has a 1-year low of $1.78 and a 1-year high of $16.64.

Kyverna Therapeutics (NASDAQ:KYTX - Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported ($1.03) EPS for the quarter, beating the consensus estimate of ($1.21) by $0.18.

Institutional Investors Weigh In On Kyverna Therapeutics

Several institutional investors have recently added to or reduced their stakes in KYTX. China Universal Asset Management Co. Ltd. bought a new stake in Kyverna Therapeutics in the 4th quarter valued at approximately $34,000. Squarepoint Ops LLC acquired a new stake in shares of Kyverna Therapeutics in the fourth quarter valued at approximately $43,000. Corton Capital Inc. bought a new stake in shares of Kyverna Therapeutics in the fourth quarter worth $45,000. Corebridge Financial Inc. lifted its position in shares of Kyverna Therapeutics by 42.3% in the fourth quarter. Corebridge Financial Inc. now owns 12,811 shares of the company's stock worth $48,000 after purchasing an additional 3,810 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Kyverna Therapeutics by 53.7% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,288 shares of the company's stock worth $53,000 after purchasing an additional 4,990 shares during the last quarter. 18.08% of the stock is owned by institutional investors.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.